Central Norway Regional Health Authority Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2017
NCT02967640
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Central Norway Regional Health Authority | Namsos Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

ketamine (ketalar) (1 trial)

Drugs in Other Trials (2)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 3)

Rotator Cuff Injuries (Phase 3)

Tendinopathy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3